Why did Pyxis Oncology stock rise on 9 October?
Written after the close on
Pyxis Oncology +2.01%
Pyxis Oncology on Nasdaq edged up as a large new investor stake drew attention.
Over the last five trading days Pyxis Oncology slipped slightly, even as the broad market and the healthcare sector both climbed, so it lagged both.
The likeliest drag was the completion of a large public offering — a sale of new shares to investors — that closed late last week and can weigh on a stock by adding supply; a fresh institutional stake disclosed earlier this week likely helped steady the last session.
A Schedule 13G is a filing that a large investor makes when it crosses a 5% ownership threshold, and the offering raised up to $282.6 million for the clinical-stage company.
Watch whether the newly disclosed holders keep building their positions or trim them.